Browse by category

The initial results of a study assessing the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence, has reported that after 12 months, the average total body weight loss was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. “These results provide additional data that a combination approach with the Allurion Smart Capsule and GLP-1 medications has several advantages,” said